Vertex Pharmaceuticals Incorporated vs Wayfair Inc — how do they compare? Vertex Pharmaceuticals Incorporated trades at $481.09 (market cap $121.95B), while Wayfair Inc trades at $84.8 (market cap $11.58B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 10.5× Wayfair Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Wayfair Inc nearer its low. Which is the better fit depends on your goals.
| VRTX | W | |
|---|---|---|
Market Cap | $121.95B | $11.58B |
Sector | Health | Consumer Cyclical |
52-Week High | $529.59 | $119.05 |
52-Week Low | $366.54 | $56.42 |
Enterprise Value | $116.69B | $14.16B |
Trailing returns across standard periods
Latest headlines on both assets
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →